8/23/2017 10:37 AM

PHA5782C: Patient Care II
Introduction to Infectious Disease and Hematology/Oncology

Fall 2017

4 Credit Hours – [A-E Grading]

Second of an eight-course sequence that prepares the student to provide patient-centered care by serving as a collaborative interprofessional team-member who is an authority on pharmacotherapy. Learning occurs through team-based learning. This course focuses on providing patient-centered care to patients who have the following disorders: infectious disease, hematology and oncology disorders. Learners will develop, integrate, and apply knowledge from the foundational disciplines (i.e., pharmaceutical, social/behavioral/administrative, and clinical sciences) and apply the Pharmacists' Patient Care Process in solving case-based scenarios of patients with infectious diseases, hematologic and oncology disorders.

Teaching Partnership Leader

Priti N. Patel, Pharm.D., BCPS

- Email: ppatel@cop.ufl.edu
- Office: St. Petersburg Campus
- Phone: 727-394-6213
- Office Hours: By appointment ONLY.

See Appendix A. for Course Directory of Faculty and Staff Contact Information.

Entrustable Professional Activities

This course will prepare you to perform the following activities which the public entrusts a Pharmacist to perform:

1. EPA A1. Collect subjective and objective data by performing a patient assessment and gathering data from chart/electronic records, pharmacist records, other health professionals and patient/family interviews.
2. EPA A2. Interpret patient data, and identify medication-related problems and develop a prioritized problem list.

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA

3. EPA A3. Formulate evidence-based care plans in collaboration with an interprofessional team. Utilize clinical guidelines in the development of a pharmacotherapy plan.
4. EPA A4. Document a patient/clinical encounter electronically/in writing.
5. EPA A5. Provide counseling and medications and health wellness (including referral when there are social determinants of health and disparities).
6. EPA A6. Assess and counsel a patient about health-wellness.
7. EPA A7. Present a succinct oral patient summary and plan to a health care provider. Defend a therapeutic plan verbally or in writing using references, guidelines, or primary literature.
8. EPA A8. Give and receive a patient handover to transition care.
9. EPA A9. Collaborate as a member of an interprofessional team and provide patient-centered care.

Course-Level Objectives

Upon completion of this course, the student will be able to:

1. **Upon completion of this course, the student will be able to provide patient-centered care for patients with one or more of the following disorders or pharmacotherapy needs:**
    a. Antibiotic stewardship
    b. Uncomplicated urinary tract infection
    c. Community-acquired pneumonia
    d. Skin and soft tissue infections
    e. Surgical prophylaxis
    f. Vulvovaginitis
    g. Influenza
    h. Anemias (iron-deficiency, B12, and folate)
    i. Lymphoma
    j. Chemotherapy-induced nausea and vomiting

2. **Specifically, given a case of a patient with one or more of the above disorders/pharmacotherapy needs:**
    a. Integrate knowledge and use clinical reasoning skills in accomplishing the following steps when managing a patient with the disease state:
        i. **Collect:** Gather subjective and objective information about the patient in order to understand the relevant medical and medication history and clinical status of the patient.
            1. Subjective and objective information is collected through patient interview, medical record review, pharmacy profile review, and communication with other members of the health care team.
            2. A holistic view is initiated during collection in order to consider physiological, psychological, and sociological variables of the patient and this view is maintained throughout the patient care process.
        ii. **Assess:** Assess the information collected and analyze the clinical effects of the patient's therapy in the context of the patient's overall health goals in order to identify and prioritize problems and achieve optimal care.
            1. Understand, explain, and assess a patient's health status.

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA

2. Interpret physical and patient assessment findings.
3. Assess each medication for appropriateness, effectiveness, safety, and patient adherence.
4. Assess health and functional status, risk factors, health data, cultural factors, health literacy, and access to medications or other aspects of care.
5. Assess immunization status and the need for preventive care and other health care services.
6. Integrate knowledge, clinical experience, and patient data to formulate and test hypotheses about the etiology of medication-related problems. (Generate hypotheses).
7. Establish potential and actual medication-related problems.

iii. **Plan:** Develop an individualized patient-centered care plan in collaboration with other health care professionals and the patient/caregiver.

1. **Therapeutic Goals:** Develop specific and general therapeutic goals for the patient. These goals achieve clinical outcomes in the context of the patient's overall health care goals and access to care.
2. **Therapeutic Plan:** Integrate knowledge, evidence-based literature/information, clinical experience, patient data, patient goals and desires, and the prescriber's judgment when developing the best pharmacotherapeutic plan for the patient.
    a. **Therapeutic Alternatives:** Evaluate pharmacotherapeutic alternatives for the patient before establishing the therapeutic plan.
    b. **Develop the Therapeutic Plan:** This plan addresses medication-related problems and optimizes medication therapy. Considerations for the plan include:
        i. Goals and desires of the patient
        ii. Application of established practice guidelines, evidence-based medicine, and population-based treatment plans in developing the plan.
        iii. Accurate and patient-specific dosing (including dosage adjustment for renal/hepatic dysfunction, starting dose, maximum doses, timing of doses and pharmacokinetic design for narrow therapeutic index drugs,).
        iv. Parameters for monitoring response and frequency of monitoring.
        v. Parameters for monitoring adverse effect and frequency of monitoring.
        vi. Plan for patient counseling/education.
        vii. Supports care continuity, including follow-up and transitions of care as appropriate.

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA

c. **Patient/Caregiver engagement:** The patient/caregiver are involved through education, empowerment, and self-management.

iv. **Implement:** Implement the care plan in collaboration with other health care professionals and the patient/caregiver. When implementing the care plan, the following are accomplished:

1. Medication and health-related problems are addressed.
2. Preventative care including vaccine administration are provided.
3. Medication therapy is initiated, modified, discontinued, or administered as authorized.
4. Education and self-management training is provided to the patient/caregiver.
5. Refers and provides transitions of care as needed.
6. Schedules follow-up care as needed to achieve goals of therapy.

v. **Follow-up (Monitor and Evaluate):** Monitor and evaluate the effectiveness of the care plan and modify the plan in collaboration with other health care professionals and the patient/care giver. The following are continually monitored and evaluated:

1. Medication appropriateness, effectiveness, and safety and patient adherence through available data, biometric test results and patient feedback.
2. Clinical endpoints that contribute to the patient's overall health.
3. Outcomes of care, including progress toward or achievement of goals.

vi. **Patient-Centered Care:** Foster a patient-centered care approach by accomplishing the following:

1. **Communicate:** Succinctly communicate with other health care team members and the patient/caregiver throughout the patient care process.
2. **Collaborate:** Discuss with team members the specific therapeutic approaches for individual patients based on scientifically and logically validated assessment of the patient's health care needs and an ethical consideration of the patient's health care goals and desires.
3. **Document:** Prepare a written communication that is well-organized, logical, complete, appropriate, and evidence-based.

b. **Apply and integrate foundational knowledge (i.e., pharmaceutical, social/behavioral/administrative**, and **clinical sciences) throughout the patient care process.** This will require the ability to:

i. Describe the pathophysiology of disease state(s) and identify appropriate drug targets (cellular/molecular), biochemical processes, and organ changes for therapeutic intervention. Specifically, for a given disease state:

1. Describe the basic pathophysiology of the disease including an explanation of the abnormal processes and the resulting disease signs and symptoms.
2. Outline risk factors and/or diagnostic indicators (e.g., lab values, diagnostic test results).

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA

3. Determine classes of drugs that will treat the disease state and ameliorate the underlying pathophysiology and signs/symptoms.

ii. Apply knowledge about structure-activity relationships and cellular/molecular mechanisms of action to identify drug classes that are appropriate for treatment of the disease state. Specifically, for each drug class:
   1. Identify the relevant therapeutic targets and explain the mechanism(s) of action.

iii. Describe major pathways for metabolism and the pharmacological/therapeutic consequences of metabolism.

iv. Compare and contrast the therapeutic and adverse effects of drug classes that are appropriate for treating the disease state.
   1. Identify the most common/serious drug interactions and adverse effects.
   2. Identify important precautions and contraindications.

v. Compare and contrast the therapeutic and adverse effects of drugs within a given class and then recommend the best drug for the patient.

vi. Recommend any unique storage, handling, or use requirements to ensure patient safety and clinical efficacy.

vii. Discuss significant pharmacokinetic and pharmacodynamic considerations.

viii. Integrate the following transcending concepts when assessing a patient and developing a care plan:
   1. Apply foundational concepts about health information and informatics (Informatics).
   2. Evaluate Superiority Randomized Controlled Trials (RCTs) and PROs and apply to a patient need (Evidence-based practice).
   3. Use clinical reasoning and clinical judgment (Problem-solving).
   4. Consider a patient/families perspective about death and dying when providing care (Behavioral considerations).
   5. Address issues related to law and ethics.
   6. Recommend Immunizations (Strategies for health-wellness).
   7. Provide aminoglycoside, vancomycin, and general antibiotic dosing recommendations (pharmacokinetics).
   8. Apply oncology pharmacogenomics (Personalized Medicine).
   9. Assess the role of herbal and dietary supplements for the immune system (Self-care: OTC, herbals-dietary supplements, CAM).
   10. Use SBAR when communicating with another health professional (Interprofessional collaboration).
   11. Consider medication safety issues related to patient care.
   12. Apply population-based care

3. Demonstrate the ability to be an effective team member by collaborating in preparing for class sessions and in solving case studies.

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA

8/23/2017 10:37 AM

Course Pre-requisites

1. Completion of all Year 1 Pharm.D. program coursework including milestones.

Course Co-requisites

1. PHA5755 Principles of Medical Microbiology, Immunology, and Virology
2. PHA 5163L Professional Practice Skills Lab III

Course Outline

Please routinely check your campus calendar and the Canvas course site for any messages about changes in the schedule including meeting dates/times, deadlines, and room changes.

Date *Recommended Dates for Independent Study*	**Mod#**	**Unit Topic**	**Contact Hours** [hr.]a	**Faculty Author**
	1	Module 1: Antimicrobials		
	1.1	Unit 1.1: Pharmacology of Antimicrobials, Part I	4.5hr	Jourjy, Klinker, Venugopalan
8/28/17	1.1.1	Watch: Introduction to Infectious Diseases	0.75hr	Jourjy
8/28/17	1.1.2	Watch: Penicillins	0.5hr	Klinker
8/28/17	1.1.3	Watch: Extended Spectrum Penicillin's	0.25hr	Klinker
8/28/17	1.1.4	Watch: Cephalosporins	0.75hr	Jourjy
8/28/17	1.1.5	Watch: Carbapenems	0.5hr	Klinker
8/29/17	1.1.6	Watch: Monobactams	0.25hr	Klinker
8/29/17	1.1.7	Watch: Glycopeptides	0.75hr	Venugopalan
8/29/17	1.1.8	Watch: Daptomycin	0.25hr	Venugopalan
8/29/17	1.1.9	Watch: Aminoglycosides	0.5hr	Klinker
	1.2	Unit 1.2: Medicinal Chemistry of Antimicrobials, Part I	1.25hr	Huigens
8/29/17	1.2.1	Watch: Beta-lactams	0.75hr	Huigens
8/29/17	1.2.2	Watch: Glycopeptides	0.5hr	Huigens
	1.3	Unit 1.3: Introduction to PK/PD	1.5hr	Bulitta

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA

8/23/2017 10:37 AM

Date *Recommended Dates for Independent Study*	**Mod#**	**Unit Topic**	**Contact Hours** [hr.]a	**Faculty Author**
8/30/17	1.3.1	Watch: Introduction to Pharmacokinetics and Pharmacodynamics – Part 1	1.25hr	Bulitta
8/30/17	1.3.2	Watch: Introduction to Pharmacokinetics and Pharmacodynamics – Part 2	1.0hr	Bulitta
	1.4	Unit 1.4: Acute Bacterial Skin and Skin Structure Infections	0.5hr	Venugopalan
8/30/17	1.4.1	Watch: Acute Bacterial Skin and Skin Structure Infections	0.5hr	Venugopalan
	1.5	Unit 1.5: Pharmacology of Antimicrobials, Part II	1.75hr	Venugopalan, Klinker, Jourjy
8/30/17	1.5.1	Watch: Oxazolidinones	0.25hr	Venugopalan
8/30/17	1.5.2	Watch: Fluoroquinones	0.5hr	Klinker
8/30/17	1.5.3	Watch: Tetracyclines	0.5hr	Jourjy
8/30/17	1.5.4	Watch: Sulfonamides	0.5hr	Klinker
8/31/17 8:30am-12:35pm	1.1-1.5	Active Learning Session 1: Skin/Soft Tissue Infection	2.0hr (4.0hr workup)	Venugopalan, Jourjy, Klinker, Huigens
	1.6	Unit 1.6: Uncomplicated Urinary Tract Infection	0.5hr	Klinker
9/1/17	1.6.1	Watch: UTI	0.5hr	Klinker
	1.7	Unit 1.7: Pharmacology of Antimicrobials, Part III	1.75hr	Klinker, Jourjy
9/1/17	1.7.1	Watch: Macrolides	0.5hr	Jourjy
9/1/17	1.7.2	Watch: Urinary agents - Fosfomycin	0.25hr	Klinker
9/1/17	1.7.3	Watch: Urinary agents - Nitrofurantoin	0.25hr	Klinker
9/1/17	1.7.4	Watch: Polymixins	0.5hr	Klinker
9/1/17	1.7.5	Watch: Clindamycin/Metronidazole	0.25hr	Jourjy
9/6/17 8:30am-12:35pm	1.6-1.7	Active Learning Session 2: UTI	2.0hr (4.0hr workup)	Klinker, Jourjy, Huigens
	1.8	Antimicrobial Stewardship	0.5hr	Klinker

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA

8/23/2017 10:37 AM

Date *Recommended Dates for Independent Study*	**Mod#**	**Unit Topic**	**Contact Hours** [hr.]a	**Faculty Author**
9/7/17	1.8.1	Watch: Antimicrobial Stewardship	0.5hr	Klinker
	1.9	Unit 1.9: Medicinal Chemistry of Antimicrobials, Part II	1.5hr	Huigens
9/7/17	1.9.1	Watch: Aminoglycoside Antibiotics	0.5hr	Huigens
9/7/17	1.9.2	Watch: Macrolide Antibiotics	0.25hr	Huigens
9/7/17	1.9.3	Watch: Tetracycline Antibiotics	0.25hr	Huigens
9/7/17	1.9.4	Watch: Fluoroquinoline Antibacterial Agents	0.5hr	Huigens
	1.10	Unit 1.10: Pharmacotherapy of Surgical Prophylaxis	0.5hr	Klinker
9/7/17	1.10.1	Watch: Pharmacotherapy of Surgical Prophylaxis	0.5hr	Klinker
	1.11	Unit 1.11: Community-acquired Pneumonia	0.5hr	Jourjy
9/7/17	1.11.1	Watch: Community Acquired Pneumonia	0.5hr	Jourjy
9/8/17 1:55-6:00pm	1.8-1.11	Active Learning Session 3: Community-Acquired Pneumonia	2.0hr (4.0hr workup)	Klinker, Jourjy, Huigens
	2	Module 2: Antifungals and Antivirals		
	2.1	Unit 2.1: Antifungals	3.0hr	Childs-Kean, Ding
9/8/17	2.1.1	Watch: Pharmacology of Antifungals	1.5hr	Childs-Kean
9/8/17	2.1.2	Watch: Medicinal Chemistry of Antifungals	1.0hr	Ding
9/8/17	2.1.3	Watch: Therapeutics of Antifungals	0.5hr	Childs-Kean
9/11/17 8:30am-12:35pm	2.1	Active Learning Session 4: Vulvovaginitis	2.0hr (4.0hr workup)	Childs-Kean, Ding
	2.2	Unit 2.2: Antivirals	3.0hr	Ding
9/12/17	2.2.1	Watch: Pharmacology of Antivirals	1.5hr	DeSear
9/12/17	2.2.2	Watch: Medicinal Chemistry of Antivirals	1.0hr	Ding
9/12/17	2.2.3	Watch: Therapeutics of Antivirals	0.5hr	DeSear

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA

8/23/2017 10:37 AM

Date *Recommended Dates for Independent Study*	**Mod#**	**Unit Topic**	**Contact Hours** [hr.]a	**Faculty Author**
9/13/17 8:30am-12:35pm	2.2	Active Learning Session 5: Influenza	2.0hr (4.0hr workup)	DeSear, Ding
	3	Module 3: Anemias		
	3.1	Unit 1.3: Pathophysiology of Anemias	1.0hr	Khoury
9/13/17	3.1.1	Watch: Pathophysiology of Anemias Part 1	0.5hr	Khoury
9/13/17	3.1.2	Watch: Pathophysiology of Anemias Part 2	0.5hr	Khoury
	3.2	Unit 3.2: Therapeutics of Anemias	1.0hr	Farland
9/13/17	3.2.1	Watch: Therapeutics of Anemias	0.75hr	Farland
9/15/17 3:00-5:30pm	1.1-2.2	Exam 1: Modules 1-2	2.0hr	
9/18/17 8:30am-12:35pm	3.1-3.2	Active Learning Session 6: Anemia	1.0hr (2.0hr workup)	Khoury, Farland
	4	Module 4: Oncology Drugs		
	4.1	Principles of Oncology Therapeutics	1.0hr	LaPlant
9/18/17	4.1.1	Watch: Principles of Oncology	1.0hr	LaPlant
	4.2	Unit 4.2: Pharmacology of Oncology Drugs, Part I	1.125hr	LaPlant
9/18/17	4.2.1	Watch: Introduction to Pharmacology of Oncology Drugs	0.25hr	LaPlant
9/18/17	4.2.2	Watch: Anthracyclines	0.25hr	LaPlant
9/18/17	4.2.3	Watch: Taxanes	0.125hr	LaPlant
9/18/17	4.2.4	Watch: Platinums	0.125hr	LaPlant
9/18/17	4.2.5	Watch: Cycle-specific	0.25hr	LaPlant
9/18/17	4.2.6	Watch: Alkylating Agents	0.125hr	LaPlant
	4.3	Unit 4.3: Pharmacology of Oncology Drugs, Part II Includes Transcending Concept: Personalized Medicine (Oncology)	2.0hr	May, Lamba

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA

8/23/2017 10:37 AM

Date *Recommended Dates for Independent Study*	**Mod#**	**Unit Topic**	**Contact Hours** [hr.]a	**Faculty Author**
9/18/17	4.3.1	Watch: Pharmacology of Oncology Drugs Part 2A	0.5hr	May
9/18/17	4.3.2	Watch: Pharmacology of Oncology Drugs Part 2B	0.5hr	May
9/18/17	4.3.3	Transcending Concept: Personalized Medicine – Oncology	1.0hr	Lamba
	4.4	Unit 4.4: Medicinal chemistry of Oncology Drugs	1.75hr	Luesch
9/19/19	4.4.1	Watch: Medicinal Chemistry of Oncology Drugs, Part 1	1.0hr	Luesch
9/19/19	4.4.2	Watch: Medicinal Chemistry of Oncology Drugs, Part 2	0.75hr	Luesch
	4.5	Unit 4.5: Non-Hodgkins Lymphoma	3.5hr	LaPlant
9/19/19	4.5.1	Watch: Non-Hodgkins Lymphoma	0.25hr	LaPlant
9/19/19	4.5.2	Watch: Hodgkins Lymphoma	0.25hr	LaPlant
9/19/19		Read: Pharmacotherapy: A Pathophysiologic Approach, 9e, Chapter 109	2.5hr	LaPlant
	4.6	Unit 4.6: Transcending Concepts **: Communicating with Terminally Ill Patients; Death and Dying	0.75hr	Normann
9/19/19	4.6.1	Watch: Death and Dying	0.25hr	Normann
9/19/19	4.6.2	Watch: Discussing Dying	0.25hr	Normann
9/19/19	4.6.3	Watch: Brene Brown on Empathy	0.125hr	Normann
9/19/19		Read: The dying patient: Choices, Control, and Communication. See Canvas.	0.125hr	Normann
9/20/17 8:30-10:25am	4.1-4.6	Active Learning Session 7: Q&A Session	2.0hr (4.0hr workup)	LaPlant, Luesch, May
	4.7	Unit 4.7: Pharmacology of Anti-emetics	0.5hr	May
9/20/17	4.7.1	Watch: Pharmacology of Antiemetics	0.5hr	May
	4.8	Unit 4.8: Medicinal Chemistry of Anti-emetics	1.0hr	Huigens

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA

8/23/2017 10:37 AM

Date *Recommended Dates for Independent Study*	**Mod#**	**Unit Topic**	**Contact Hours** [hr.]a	**Faculty Author**
9/20/17	4.8.1	Watch: Medicinal Chemistry of Anti-emetics, Part I	0.5hr	Huigens
9/20/17	4.8.2	Watch: Medicinal Chemistry of Anti-emetics, Part II	0.5hr	Huigens
	4.9	Unit 4.9: Therapeutics of Antiemetics	0.75hr	May
9/20/17	4.9.1	Watch: Nausea and Vomiting Therapeutics	0.75hr	May
	4.10	Unit 4.10: Transcending Concepts**: Informatics, Interprofessional (SBAR), Medication Safety and Patient Safety (Drug Therapy Problems Related to Access)	0.5hr	
9/20/17	4.10.1	Watch: Patient Assistance Programs	0.5hr	Smith
	4.11	Unit 4.11: Transcending Concepts**: Self-Care – Herbal & dietary supplements for the Immune System,	0.75hr	Grundmann
9/20/17	4.11.1	Watch: Self-care: Herbal and Dietary Supplements for the Immune System	0.75hr	Grundmann
	4.12	Unit 4.12: Transcending Concepts**: Superiority RCTs and PROs,	0.5hr	Patel
9/20/17	4.12.1	Watch: Oncology Trials	0.5hr	Patel
9/21/17 8:30am-12:35pm	4.7-4.12	Active Learning Session 8: Lymphoma, Nausea, and Vomiting in the Cancer Patient	4.0hr	LaPlant, Luesch, Huigens, May, Grundmann, Patel, Lamba, Normann
9/22/17 1:55-6:00pm	1.1-4.12	Active Learning Session 9: Capstone	4.0hr	Venugopalan, Jourjy, Ding, Klinker, Childs-Kean, May, Khoury, Farland, Lamba, Luesch, LaPlant, Normann, DeSear, Smith, Patel

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA

8/23/2017 10:37 AM

Date *Recommended Dates for Independent Study*	**Mod#**	**Unit Topic**	**Contact Hours** [hr.]a	**Faculty Author**
9/25/17 1:55-4:25pm	1.1-4.12	Final Exam: Comprehensive	2.5hr	
		Total Contact Hours in Course:	75hr	

Required Textbooks/Readings

1. Foye WO, Lemke T, Williams DA. Foye's Principles of Medicinal Chemistry, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PA, 7th Edition, 2013. ISBN-13:978-1609133450; ISBN-10:1609133455
    - Not Available via HSC Library (Purchased as a 1PD)
2. Brunton L. Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill Professional, New York, NY, 12th Edition, 2011. ISBN-13:978-0071624428; ISBN-10:0071624422
    - Available via HSC Library – Access Pharmacy
3. Dipiro, J, Talbert R, Yee G, Matzke G, Wells B, Posey L. Pharmacotherapy – A pathophysiologic approach. McGraw-Hill Professional, New York, NY, 10th Edition, 2017. ISBN 978-1-259-58748-1
    - Available via HSC Library – Access Pharmacy
4. Krinsky DL, Ferreri SP, Hemstreet B, et al. Handbook of nonprescription drugs: An interactive approach to self-care. 18th ed. Washington, D.C.: American Pharmacists Association; 2015. ISBN-13: 978-1582122250
    - Not Available via HSC Library (Purchased as a 1PD)
5. Primary literature readings will be posted in Canvas.

Use UF VPN to access UF Libraries Resources when off-campus. The UF HSC library staff can assist you with questions or issues related to accessing online library materials. For assistance contact your College of Pharmacy librarian or visit the HSC Library Website at this URL: http://www.library.health.ufl.edu/

Suggested Textbooks/Readings

Suggested readings will be posted in Canvas.

Other Required Learning Resources

Neehr Perfect

- Neehr Perfect is an educational EHR used throughout the PharmD curriculum. Students will be expected to purchase a subscription to this program.
- Create your Neehr Perfect account by going to: http://neehrperfect.com. Select **Subscribe** in the upper, right corner and enter the following Pharmacy Student Program Key: **S96Y29**

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA

- Follow the on-screen instructions to create your account and apply your subscription. Refer to the Canvas page for skills labs for more detailed information
    - 1PDs are encouraged to purchase a 3 year Student Subscription
    - 2PDs are encouraged to purchase a 2 year Student Subscription
    - 3PDs are encouraged to purchase an Academic Year Student Subscription

Materials & Supplies Fees

None

Student Evaluation & Grading

Evaluation Methods and How Grades are calculated.

Assessment Item	Grade Percentage
iRATs (6 @ 2.5% ea.) *Single lowest score dropped.	12%
tRATs (7 @ 3.57% ea.)	20%
Capstone submission	8%
Exam 1	25%
Final Exam	35%
Total	100%

Table 1. Grading Scale

Percentage Range	Letter Grade
92.50-100%	A
89.50-92.49%	A-
86.50-89.49%	B+
82.50-86.49%	B
79.50-82.49%	B-
76.50-79.49%	C+
72.50-76.49%	C
69.50-72.49%	C-
66.50-69.49%	D+
62.50-66.49%	D
59.50-62.49%	D-
< 59.50%	E

Rounding of grades:

Final grades in Canvas will be rounded to the 2nd decimal place. If the decimal is X.495 or higher, Canvas will round the grade to X.50. The above scale depicts this policy and grades are determined accordingly. Grade assignment is made using this policy and NO EXCEPTIONS will be made in situations where a student's grade is "close."

Educational Technology Use

The following technology below will be used during the course and the student must have the appropriate technology and software.

1. ExamSoft™ Testing Platform
2. Canvas™ Learning Management System

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA

8/23/2017 10:37 AM

For technical support, navigate to Educational Technology and IT Support Contact Information at this URL: http://curriculum.pharmacy.ufl.edu/current-students/technical-help/

Pharm.D. Course Policies

The Policies in the following link apply to this course. Review the Pharm.D. Course Policies carefully, at this URL: http://curriculum.pharmacy.ufl.edu/current-students/course-policies/

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA

8/23/2017 10:37 AM

Appendix A. Course Directory

Teaching Partnership Leader/Course Director:

Priti N. Patel, Pharm.D., BCPS
Email: ppatel@cop.ufl.edu
Office: St. Petersburg Campus
Phone: 727-394-6213

Questions to Ask:

- Questions about grades
- Concerns about performance
- Guidance when there are performance problems (failing grades)
- General questions about content

Academic Coordinator:

Name: Sarah Burgess, M.Ed
Email: sburgess@cop.ufl.edu
Office: HPNP 4312
Phone: 352-273-5617
Absence Email: absent2pd@cop.ufl.edu

Educational Coordinators:

Name: McKenzie Wallen
Email: mwallen@cop.ufl.edu
Office: Jacksonville Campus

Name: Victoria Savosh
Email: vsavosh@cop.ufl.edu
Office: Orlando Campus

Questions to Ask:

- Issues related to course policies (absences, make up exams, missed attendance)
- Absence requests (Only the Academic Coordinator handles absence requests)
- Questions about dates, deadlines, meeting place
- Availability of handouts and other course materials
- Assignment directions
- Questions about grade entries gradebook (missing grades, wrong grade)
- Assistance with ExamSoft® (Distant campus students may contact Education Coordinator for use of SofTest and assistance during exams. The Academic Coordinator is the contact person for issues related to grading and posting of ExamSoft grades.)

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA

8/23/2017 10:37 AM

Other Teaching Partnership Faculty Members:

Jürgen Bulitta, Ph.D.
Email: jbullita@cop.ufl.edu
Office: ORL 475
Phone: 407-313-7010

Kate Desear, Pharm.D.

Yousong Ding, Ph.D.
Email: yding@cop.ufl.edu
Office: HSC P6-27
Phone: 352-273-7742

Michelle Farland, Pharm.D., BCPS, CDE
Email: mfarland@cop.ufl.edu
Office: HPNP 3307
Phone: 352-273-6293

Oliver Grundmann, Ph.D.
Email: grundman@ufl.edu
Phone: 352-246-4994

Emily Huesgen, Pharm.D., BCACP, AAHIVP
Email: ehuesgen@cop.ufl.edu
Office: HPNP 2302
Phone: 352-273-6365

Robert Huigens III, Ph.D.
Email: rwhuigens@ufl.edu
Office: HSC P5-33
Email: 352-273-7718

Andrew Y. Hwang, Pharm.D.
Email: ayhwang@cop.ufl.edu
Phone: 352-265-9553

Jackie Jourjy, Pharm.D., BCPS
Email: jjourjy@cop.ufl.edu
Office: Lake Nona/ORL
Phone: 407-313-7006

Lindsey Childs-Kean, Pharm.D., MPH
Email: lchilds-kean@cop.ufl.edu
Phone: 727-394-6213

Adonice Khoury, Pharm.D.
Email: akhoury@cop.ufl.edu
Phone: 352-273-8136

Kenneth Klinker, Pharm.D.
Email: klinkkp@cop.ufl.edu
Office: HSC P4-31
Phone: 352-265-0111, ext. 45892

Jatinder Lamba, Ph.D., M.Sc.
Email: jlamba@cop.ufl.edu
Office: HSC PG-25
Phone: 352-273-6425

Hendrik Luesch, Ph.D.
Email: luesch@cop.ufl.edu
Office: HSC P3-12
Phone: 352-273-7738

Kourtney LaPlant, Pharm.D.
Email: kourtney.laplant@va.gov
Office: VA/GNV
Phone: 352-548-6000, ext. 4428

Paige May, Pharm.D.
Email: paige.may@va.gov
Office: VA/GNV
Phone: 352-548-6000, ext. 4426

Sven Normann, Pharm.D., DABAT
Email: normann@cop.ufl.edu
Office: HPNP 4323
Phone: 352-273-6305

Kaylie Smith, Pharm.D.

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA

8/23/2017 10:37 AM

Veena Venugopalan, Pharm.D., BCPS
Email: vvenugopalan@cop.ufl.edu
Office: HPNP 2314
Phone: 352-272-6217

COPYRIGHT © 2017 UNIVERSITY *of* FLORIDA